Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands
Procedural expertise: URS, PCNL, RIRS, TURP, TURBT, and major open urological surgery
Its true that we dont yet have robust clinical trial data supporting the efficacy of GLP-1 microdosing, especially when compared head-to-head with full-dose protocols
Similarly the quantity of PT-141 administered may not be sufficient, if administered as monotherapy, to independently initiate the desired pharmacological response in the patient
HUBERMAN: So when people are combining different things in cocktail, it's not necessarily a bad thing, but you want to make sure that you're working with someone who's very familiar with peptides
What is not debated is that the defense is real